MGX · Metagenomi Therapeutics, Inc. · Executive Compensation

$0.81 +0.03 (+3.55%) At close · Oct 19

Market Cap

$29.62M

37.78M

Volume · Oct 19 155.96K Avg daily vol (3M) 157.61K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jian Irish	Ph.D., M.B.A. President and Chief Executive Officer	$570,655	—	$427,960	$402,782	$252,590	$13,933	$1,667,920
Brian C. Thomas	Former Chief Executive Officer	$563,014	—	$42,240	$191,061	—	$599,746	$1,396,061
Pamela Wapnick	M.B.A. Chief Financial Officer	$464,000	—	$210,480	$81,883	$161,101	$17,500	$934,964
Matthew L. Wein	General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary	$407,151	—	$163,401	$43,476	$124,856	$17,500	$756,384

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian C. Thomas	Chief Executive Officer	$628,333	—	$1,287,493	$3,860,492	$265,200	$19,766	$6,061,284
Jian Irish	Ph.D., M.B.A. President and Chief Operating Officer	$536,333	—	$762,496	$2,286,313	$187,000	$11,293	$3,783,435
Pamela Wapnick	M.B.A. Chief Financial Officer	$445,000	—	$749,999	$2,248,828	$122,400	$14,413	$3,580,640
Matthew L. Wein	General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary	—	—	—	—	—	—	—
General Counsel	Compliance Officer, Head of BD&L and Corporate Secretary	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian C. Thomas	Chief Executive Officer	$516,667	$20,000	$6,966,519	—	$288,600	$34,069	$7,825,855
Jian Irish	Ph.D., M.B.A. President and Chief Operating Officer	$465,000	$15,000	$1,783,211	—	$231,449	$18,368	$2,513,028
Pamela Wapnick	M.B.A. Chief Financial Officer	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Eric Bjerkholt, M.B.A.	Class II Director	Appointed	2026-06-09	2026-06-10
Juergen Eckhardt, M.D., M.B.A.	Class II Director	Appointed	2026-06-09	2026-06-10
Brian C. Thomas, Ph.D.	member of the Board	Resigned	2026-06-09	2026-06-10
Eric Bjerkholt	director	Appointed	2025-01-27	2025-01-16

Leadership

Jian Irish CEO, COO, Board Member
Pamela Wapnick CFO
Matthew L. Wein General Counsel
Eric Bjerkholt Board Member
Eric Bjerkholt, M.B.A. Board Member
Juergen Eckhardt Board Member
Juergen Eckhardt, M.D., M.B.A. Board Member
Laurence Reid Board Member
Willard H. Dere Board Member

Key facts CIK 1785279 CUSIP 59102M104 13F (30d) 2 filings 2 filers Visit website Investor relations